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Ionizing radiation (IR) is a mutagen that promotes
tumorigenesis in multiple exposure contexts. One
severe consequence of IR is the development of sec-
ond malignant neoplasms (SMNs), a radiotherapy-
associated complication in survivors of cancers,
particularly pediatric cancers. SMN genomes are
poorly characterized, and the influence of genetic
background on genotoxin-induced mutations has
not been examined. Using our mouse models of
SMNs, we performed whole exome sequencing of
neoplasms induced by fractionated IR in wild-type
and Nf1 mutant mice. Using non-negative matrix
factorization, we identified mutational signatures
that did not segregate by genetic background or
histology. Copy-number analysis revealed recurrent
chromosomal alterations and differences in copy
number that were background dependent. Pathway
analysis identified enrichment of non-synonymous
variants in genes responsible for cell assembly and
organization, cell morphology, and cell function and
maintenance. In thismodel system, ionizing radiation
and Nf1 heterozygosity each exerted distinct influ-
ences on the mutational landscape.INTRODUCTION
Therapy-induced malignancies, or second malignant neo-
plasms (SMNs), are severe late complications developing in
survivors of childhood cancers (Crump and Hodgson, 2009).
SMNs develop after prior exposure to mutagenic agents
such as radiotherapy and some chemotherapies, and they
are a major cause of morbidity and mortality in childhood
cancer survivors (Armstrong et al., 2009a, 2009b; Bhatia and
Sklar, 2002; Meadows et al., 2009). Most SMNs are associ-
ated with radiotherapy, which typically delivers fractionated,
focal treatment using ionizing radiation (IR) (Bhatia and
Sklar, 2002). While genotoxin exposure clearly drives SMN
development, the genetic basis for this late complication is
not understood.Cell RepIR is also a well-recognized and relevant mutagen in numerous
aspects of modern human life, and diverse exposures include
clinical radiotherapy, occupational exposure to nuclear-pow-
ered devices, nuclear fallout and waste, and diagnostic medical
imaging. It is thus important to characterize the genetic conse-
quences of IR exposure in the context of malignancy induction,
a complication with significant implications for both the affected
individual and society.
Next generation sequencing has permitted the characteriza-
tion of genomes and mutational processes in diverse cancers,
generating insights into the genomic events in tumor formation
and identifying genetic mechanisms directly responsible for
many human cancers. Known mutagens, such as UV radiation
and tobacco, have been shown to produce characteristic muta-
tional signatures (Alexandrov et al., 2013a). Mutagen dose,
length of exposure, timing in relation to an individual’s lifespan,
and genetic background are important variables influencing
mutagenicity; however, studies of mutagen-associated human
cancers generally cannot precisely define these variables or
attribute mechanisms to a specific variable. In human SMNs,
IR localization, dosing, and timing are clinically defined and differ
greatly between patients. This heterogeneity can complicate
characterizations of IR-induced tumorigenesis.
The genome-wide consequences of exposure to IR, and
whether malignancies induced by IR exposure share large- or
small-scale mutational motifs, are not known. IR produces
multiple types of DNA injury, including double-strand breaks
(Yong et al., 2014), which differ fromUV-induced genetic lesions,
and thus IR-induced malignancies might possess a mutational
landscape that is distinguishable from those of UV or other
mutagens.
In prior studies we developed experimental mouse models
of SMNs by delivering focal fractionated radiation similar to
that used in clinical radiotherapy to both Nf1 mutant and wild-
type mice. Irradiated mice of both genotypes developed diverse
solid and hematologic malignancies consistent with radio-
therapy-induced SMNs that arise in irradiated cancer survivors
(Choi et al., 2012; Nakamura et al., 2011). These neoplasms
are unique biospecimen because in contrast to clinical SMNs
samples, both the genetic background of the mouse model
and the mutagen (IR) exposure were well-defined. To charac-
terize the genomes of these malignancies, we performed whole
exome sequencing, comparing the exomes of malignancies
arising in wild-type and Nf1 mutant backgrounds to determineorts 12, 1915–1926, September 22, 2015 ª2015 The Authors 1915
Figure 1. Numbers and Types of Substitu-
tions in Sequenced Samples
Summary of tumors sequenced and the fre-
quencies of mutations seen.
(A) Types and numbers of primary radiation-
induced malignancies from wild-type and Nf1
mutant mice that were analyzed by whole exome
sequencing.
(B) Synonymous and non-synonymous SNVs in
each sample. Malignancies from Nf1 mutant
mice are in black, and wild-type (WT) are in gray
(CA, carcinomas; Pheos, pheochromocytomas;
Lymphoid, lymphoid malignancies).
(C) Frequencies of specific types of base sub-
stitutions in SNVs pooled from all samples.
(D) Composition of SNVs in Nf1 mutant and
wild-type sarcomas, corrected for total number of
mutations.
See also Tables S1 and S2–S4.whether germline tumor suppressor loss, present in the Nf1
heterozygous background, influences the mutational spectrum.
These data represent in-depth genomic characterization of
malignancies initiated by fractionated focal IR recapitulating
setup and dosimetry found in radiotherapy. Distinct, reproduc-
ible mutational signatures characterize malignancies arising
after IR. The genetic background influenced copy-number alter-
ations in IR-induced malignancies, with the genomes of tumors
arising in wild-type mice having significantly more copy-number
gains compared to tumors arising in Nf1+/ mice. These data
suggest distinct contributions of IR and background in the muta-
tional landscape of IR-induced malignancies.
RESULTS
Mutation Frequency in Tumors Generated by
Fractionated IR
We sequenced 25 malignancies arising from our mouse models
of IR-induced SMNs as diverse histologies, including soft tissue
sarcomas, squamous cell carcinoma, mammary carcinomas,
pheochromocytomas, and hematopoietic malignancies (Fig-
ure 1A). All malignancies were induced by focal, fractionated
IR as previously described (Choi et al., 2012; Nakamura et al.,
2011). Briefly, mice were irradiated at 5–8 weeks of age, targeted
to the abdominal wall, specifically the mammary glands. In addi-
tion to anatomic targeting replicating that received by patients,
the mice received identical dosing schema, which consisted of
3-Gy daily fractions (5 days a week) to total doses of 30 Gy.
We sequencedmalignancies from 19mice, with 15malignancies
arising in F1 Nf1mutant mice and 7 malignancies arising in wild-
type mice. Three tumor cell lines established from three primary
tumors (matched primary tumor and cell line pairs) were also
sequenced. 158-fold mean exome coverage was obtained. A
total of 6,623 single nucleotide variants (SNVs) were identified,
of which 4,633 were non-synonymous for an average of 265 total
SNVs and 184 non-synonymous SNVs per sample (Table S1).1916 Cell Reports 12, 1915–1926, September 22, 2015 ª2015 The AuthorsHistologies varied with regard to the
numbers of somatic non-synonymous
SNVs detected (range, 22–594), with allclasses of malignant histologies demonstrating similarly variable
numbers (Figure 1B). IR-induced sarcomas from wild-type mice
had on averagemore SNVs (mean, 290; range, 22–834) than sar-
comas from Nf1+/ mice (mean, 128; range, 48–368) (p value <
0.00001 by z test for rate ratios). Comparable averages for all
cancer types were 320 and 239 (p value < 0.00001). The genetic
backgrounds did not differ in relative frequency of synonymous
and non-synonymous SNVs (Table S2). Most nucleotide substi-
tutions were C/T or G/A transition mutations (Figure 1C).
These substitutions predominated in both synonymous and
non-synonymous variants (Table S3).
The cohort composition precluded a robust comparison of
SNV numbers between each of the different specific histologies.
However, because sarcomas arose frequently in our mouse
models (Choi et al., 2012; Nakamura et al., 2011) and are well-
recognized SMNs after radiotherapy (Henderson et al., 2007;
Tucker et al., 1987), we were able to carry out more in-depth an-
alyses for this histology (Figure 1A). Both sarcomas derived from
Nf1 mutant and wild-type mice demonstrated similar types and
frequencies of base substitutions (Figure 1D), suggesting that
the predominant types of base substitutions were not Nf1
dependent. Dinucleotide substitutions, common in UV-associ-
ated malignancies (Alexandrov et al., 2013a), were relatively
uncommon in our samples (Table S4). Non-synonymous SNVs
can have diverse consequences, and we used SNPEff software
(Cingolani et al., 2012) to summarize the predicted impact of
non-synonymous somatic variants arising in our cohort of malig-
nancies (Table 1). This analysis revealed that most variants were
missense variants of medium impact, followed by stop gains
classified as high impact.
Mutational Signature Analysis of IR-Induced
Malignancies
Mutational signature analyses have not previously been per-
formed for IR-induced tumors or NF1-associated tumors. Pat-
terns of nucleotide substitutions in tumor genomes may reflect
Table 1. Predicted Impact of Variants
High Impact Medium Impact Low Impact
Stop gained 245 missense variant 4326 mature miRNA
variant
2
Stop lost 6 initiator codon
variant
9
Splice acceptor
variant
4 stop retained
variant
2
Splice donor
variant
1 coding sequence
variant
1
Total 256 4338 2
SNPEff software was used to score the somatic substitutions for pre-
dicted biologic impact based on the resulting codon change. Predicted
impact is organized into high, medium, and low impact.specific mutational mechanisms (Alexandrov et al., 2013a,
2013b; Wei et al., 2011). In addition, mutational asymmetries
between transcribed and untranscribed strands can result from
intrinsic biases in mutation and repair mechanisms (Green
et al., 2003) and have been shown to be associated with specific
tumor types (Rubin and Green, 2009; Sjo¨blom et al., 2006; Ste-
phens et al., 2005), although the precise molecular mechanisms
responsible for the enrichment of specific mutational patterns
are not well-understood. IR-induced tumors might be hypothe-
sized to display unique mutational signatures on the basis of
the distinct type of DNA damage associated with IR. We applied
non-negative matrix factorization (NMF), as developed at the
Wellcome Trust Sanger Institute (WTSI) (Alexandrov et al.,
2013a, 2013b), to whole exome sequencing data from 25 malig-
nancies. Six possible substitutions are considered, based on the
pyrimidine in the reference position and including the proximal
sequence context (one nucleotide 50 and 30). We also performed
separate analyses of non-synonymous substitutions only versus
combined non-synonymous and synonymous substitutions.
Substitutions were also analyzed by whether the altered pyrimi-
dine was on the transcribed or untranscribed strand.
This analysis extracted three stable mutational signatures,
which were assessed by plotting signature stability and the
average Frobenius reconstruction error, measures introduced
by WTSI to assess quality features of NMF (Alexandrov et al.,
2013b) (Figure S1). Figure 2A shows the distribution of the six
possible mutation types in the three signatures. Each sub-graph
represents one substitution (e.g., A/C when A in the reference
genome is mutated to C in the sample). The bars within each
sub-graph include the nucleotides in the reference genome on
either side of the mutation location and strand (transcribed
versus untranscribed). This analysis reveals that the incidence
of specific substitutions varies in relation to the flanking nucleo-
tides, or 50 and 30 neighbors. Signature 1 harbored the most
variants of the three signatures and is characterized by C/T
substitutions distinguishable from signatures 2 and 3 because
neither the flanking 50 nor 30 base significantly influence the sub-
stitution frequency (Figure 2A). Signature 2 is enriched for C/T
substitutions when the flanking 50 base is thymine (Figure 2A).
Signature 3 is notable for a significantly increased frequency of
discrete G(C/G)C and C(T/G)T substitutions.Cell RepThe mutational signature exposures, or proportion of each
neoplasm’s mutations that are represented in one of the ex-
tracted mutational signatures, is shown in Figure 2B. All three
signatures were represented in most of the neoplasms, although
to variable extents. There was no enrichment of a single muta-
tional signature by either histologic type or genetic background.
The mutational signature exposures failed to differentiate by the
number of SNVs present in a sample.
To determine whether the three mutational signatures were
driven disproportionately by those samples harboring the great-
est numbers of substitutions, NMF analysis was performed after
excluding the 33 most mutated samples, leaving 22 in total
(Figure S2). This yielded the same three mutation signatures,
indicating that these signatures were not driven by hypermu-
tated samples.
Restricting the analysis to non-synonymous substitutions
(4,633 variants in 25 samples) also yielded the same 3 signa-
tures, and restricting to synonymous substitutions (1,990 vari-
ants in 25 samples) was unable to reliably extract the third,
but robustly produced the first and second signatures, sug-
gesting that the mutational signatures did not discriminate
between non-synonymous and synonymous variants. Corre-
lation coefficients were calculated for signatures generated
from non-synonymous SNVs only and both non-synonymous
and synonymous SNVs, demonstrating that for each mutational
signature, the correlation coefficients are greater than 0.9 be-
tween these analyses of non-synonymous only and both non-
synonymous and synonymous SNVs (Table S5). Spindle graphs
(Figure 2C) display the similarity among the coefficients with
non-synonymous only (blue) and both non-synonymous and
synonymous (orange) analyses.
In order to compare the three signatures derived from our
mouse tumors with signatures previously described by WTSI
for human cancers (Alexandrov et al., 2013a), the three signa-
tures were normalized by the trinucleotide frequencies in the
mouse genome (Frenkel et al., 2011). The coefficients of the 22
signatures reported by WTSI were correlated with the coeffi-
cients of our 3 signatures (Table S6). Our signatures 1 and 2
were not highly correlated with any of the WTSI (maximum cor-
relations of 0.685 and 0.593). Signature 3, on the other hand,
correlated 0.89 with WTSI signature 17. WTSI describe this
signature as found in colorectal, liver, lymphoma, and stomach
cancers (Alexandrov et al., 2013a). While 0.89 is a fairly strong
correlation, it should be noted that the signatures considered
as separate in the WTSI analysis have correlations as high as
0.90 (Table S6).
These signatures also demonstrated a transcriptional strand
bias for specific substitution contexts (Table S7). Fisher’s exact
test returned a p value of < 0.000001 for transcribed and untran-
scribed strands by mutation type. Specific patterns of substitu-
tions (G(T/C)T, T(C/A)G, T(C/A)T, T(T/G)C, T(T/G)G
(p < 0.01)) were highly significant for preferentially involving the
transcribed strand.
Copy-Number Analysis
Copy-number variations (CNVs) were detected employing
Control-FREEC (Boeva et al., 2012), using standard parame-
ters and the germline sequencing as a control. We observedorts 12, 1915–1926, September 22, 2015 ª2015 The Authors 1917
Figure 2. Mutation Signature Analysis
Mutation signature analysis was performed on
non-synonymous and synonymous substitutions
in 25 samples.
(A) Three discrete mutational signatures were
identified. The plots show the distribution of the
six mutation types defined by the pyrimidine base
in each signature, as inferred from the NMF pro-
cedure. Each sub-graph within a signature repre-
sents one substitution (e.g., A/C when A in the
reference genome is mutated to C in the sample).
The bars within each sub-graph include the nu-
cleotides in the reference genome on either side of
the mutation location. All trinucleotide combina-
tions are subdivided as to whether the pyrimidine is
on the transcribed (blue) or untranscribed (pink)
strand. The error bars represent ± SE of the co-
efficients calculated over the replications of the
extraction process.
(B) The distribution of each of the three signatures
in each of the 25 radiation-induced tumors is
shown. The left panel plots the numbers of sub-
stitutions comprising each signature. The right
panel displays a normalized plot.
(C) Spindle plots depict the similarity of signa-
tures derived from different subsets of the data.
Horizontal lines indicate the coefficients for 192
mutation types (including substitution based on
pyrimidine reference, strand, and flanking nucleo-
tides) of the three signatures, sorted from bottom
to top in the same order as (A) is sorted left to right.
All 3 panels have the same 3 figures on the left: 3
signatures extracted from 25 samples using both
synonymous and non-synonymous mutations.
Panels i–iii compare the three signatures extracted
using both synonymous and non-synonymous
SNVs (left, blue) versus signatures extracted using
only non-synonymous SNVs (right, red). Panels
iv–vi compare the three signatures for non-syn-
onymous and synonymous SNVs using 25 sam-
ples (left, blue) versus the three signatures for
non-synonymous and synonymous SNVs in 22
samples (excluding the three most mutated sam-
ples) (right, red).
See also Figures S1 and S2 and Tables S5, S6,
and S7.both large-scale and focal copy-number changes, as well as
tumors with relatively normal ploidy, across all histologies
(Figure 3A; Table S8). To compare patterns of copy-number
alterations between sarcomas developing in Nf1 mutant or
wild-type mice, we generated a dendrogram showing sam-
ple relatedness when clustering the data by Ward’s method
(squared Euclidean distance, variables normalized using
Z scores) using the WGCNA R software package (Figure
3B) (Langfelder and Horvath, 2008). Apart from one wild-type
sarcoma showing almost genome-wide copy-number gain,
sarcomas from the wild-type background cluster (Figure
3D). Sarcomas arising in Nf1 mutant mice also cluster, sug-1918 Cell Reports 12, 1915–1926, September 22, 2015 ª2015 The Authorsgesting an influence of Nf1 heterozy-
gous background on CNV in IR-induced
sarcomas.We also used Control-FREEC to analyze CNVs in the group
as a whole, in pooled Nf1 mutant-derived tumors only and
pooled wild-type tumors only (Figure 3A). Overall, Nf1 mutant-
derived samples showed far more copy-number losses than
gains compared to wild-type-derived samples (29% versus
11%), while wild-type derived tumors showed the opposite
pattern, harboring more gains than losses (33% versus 8%)
(Table S9). This observation holds true when considering sar-
comas only (Table S9). One notable area of copy-number loss
in Nf1mutant-derived samples is found in chromosome 11 (Fig-
ure 3B; Table S8), whose loss spans the Nf1 and Trp53 genes. In
earlier work we found this area to be characterized by loss of
heterozygosity (LOH) involving the wild-type Nf1 allele (Choi
et al., 2012).
We assessed whether genes most frequently affected by
copy-number change were similarly altered between sarcomas
arising in different genotypes (Figure 3C). Only a small fraction
of genes involved both gain and loss in the pooled samples (Fig-
ure 3C), suggesting that these genes are unlikely to function as
cancer drivers. Interestingly, sarcomas arising in Nf1 mutant or
wild-type backgrounds shared a significant fraction of genes
with copy-number alterations. To investigate whether known
cancer-causing mutations are in regions with known CNVs, we
calculated the percentage of genes in the COSMIC database
that involve either copy-number gain or loss in all sarcomas,
Nf1 mutant sarcomas, or wild-type sarcomas (Figure 3D). We
saw a significantly higher percentage of COSMIC annotated
genes that were affected by copy-number loss than gain, sug-
gesting that loss may drive tumorigenesis more so than gain.
To determine whether the mutational rate changed signifi-
cantly across the exome, and to determine whether mutational
hotspots and CNV correlate in general, we segmented the
exome into windows of 15,000 base increments and plotted
number of mutations with CNVs as estimated by Control-FREEC
software. The two were not related overall and failed to demon-
strate a correlation between areas of copy-number alterations
and SNVs. Correlations calculated over windows within each
chromosome were <0.2 for all chromosomes and <0.1 for all
but two, indicating that somatic SNVs did not co-localize with
areas of copy-number alterations.
Pathway Analysis
To determine whether sarcomas from mutant and wild-type
backgrounds utilized common or distinct pathways for tumori-
genesis, we used Ingenuity Variant Analysis software (http://
www.ingenuity.com/products/variant-analysis) to identify recur-
rently mutated pathways (Table 2). We also analyzed the tumor
exomes for recurrently mutated genes (Table 3). Sarcomas
from both genetic backgrounds shared mutational involvement
of pathways influencing cellular assembly and organization,
and cellular function and maintenance (Table 2). Interestingly,
cell cycle and cell signaling pathways were among the most
significantly mutated pathways in sarcomas from wild-type
mutant mice, suggesting a specific role for these pathways in
promoting tumorigenesis in the wild-type background.
Mutations involving the Ras pathway are common in human
cancers (Stephen et al., 2014). Analysis of Ras pathway genes
demonstrating significant copy-number changes (either loss or
gain), missense mutations, and/or stop-gain mutations in IR-
induced neoplasms indicate Ras pathwaymutations as common
in neoplasms arising from either the wild-type or Nf1 mutant
backgrounds (Figure 4). Interestingly, H-ras, K-ras, and N-ras
mutations are absent from neoplasms arising in Nf1 mutant
mice, consistent with Nf1-driven tumorigenesis being exclusive
of somatic ras mutations.
DISCUSSION
These data describe (1) the mutational landscape of malig-
nancies induced by IR and (2) the influence of the genetic back-Cell Repground, specifically heterozygosity for Nf1, upon the mutational
process. Our experimental paradigm reproducibly delivered
IR to wild-type orNf1mice, allowing for the comparison of muta-
tional processes between these backgrounds.
In humans, IR-induced malignancies arise after varying
amounts of radiation exposure, fractionation, and anatomic
localization. This variation can potentially complicate efforts to
compare mutational landscapes in the diverse neoplasms
associated with IR-induced mutagenesis. Thus, the controlled
parallels between ourmousemodels and human IR-inducedma-
lignancies are important and underpin the relevance of this
study. Murine studies of radiation mutagenesis traditionally
have been limited in their abilities to replicate clinical parameters.
For example, murine studies of radiation-induced tumors have
employed low-dose total body irradiation (TBI), a simple tech-
nique (Mao et al., 2005, 2008; Ullrich et al., 1987, 1996). Unfortu-
nately this bears little resemblance to clinical practice, where
most irradiated patients receive fractionated, focal, high-dose
irradiation (40–70 Gy) to a site of disease, and adjacent normal
tissues at risk for mutagenesis can receive up to 100% of the
prescribed dose. Replicating the dosimetry and anatomic target-
ing of radiotherapy is critical tomodeling SMNs becausemultiple
studies indicate an important relationship between radiation
dose and SMN risk in cancer survivors (Tucker et al., 1987;
Tukenova et al., 2011), with increasing doses associated with
increasing risk of solid tumors. Furthermore, as discussed
above, focal radiation and the anatomic space irradiated are in-
dependent factors influencing the risk of SMNs. To overcome
the limitations in traditional models of radiation-induced tumori-
genesis, we replicated radiotherapy approaches used in patients
to develop clinically relevant models of radiotherapy-induced
malignancies in mice, developing the first SMN models that
recapitulate anatomically appropriate SMNs in a dose-depen-
dent fashion (Choi et al., 2012; Nakamura et al., 2011).
The Nf1 mutant background is markedly sensitized to IR-
induced malignancies compared to wild-type mice, as reflected
by both higher total numbers of IR-induced tumors and worse
overall survival due to cancer development (Choi et al., 2012).
Our analysis provides an opportunity to begin to understand
the basis for this background-dependent susceptibility to IR.
The apparent susceptibility of Nf1 mutant mice to IR-induced
malignancies might suggest that malignancies from the Nf1
mutant background can reach detectable size (suggestive of a
growth advantage) even when harboring fewer SNVs than
IR-induced malignancies arising in the wild-type background.
Alternatively, if Nf1 heterozygosity compromised key mecha-
nisms of genomic stability, neoplasms arising in Nf1 mutant
mice might appear consistently hypermutated. Our data support
the former prediction that an Nf1-dependent increase in the
cancer-promoting efficiency of IR is associated with reduced
numbers of SNVs. Notably, sarcomas arising in irradiated Nf1
mutant mice harbored significantly fewer somatic variants than
sarcomas arising in irradiated wild-type mice, indicating that
heterozygosity for the Nf1 tumor suppressor gene reduces the
average number of mutations present in a tumor.
Prior studies have shown that different tumor types can differ
substantially in the types of base substitutions that dominate
their mutational signature (Sjo¨blom et al., 2006). For example,orts 12, 1915–1926, September 22, 2015 ª2015 The Authors 1919
Figure 3. Copy-Number Alteration Shared between WT and Nf1 Mutant Backgrounds
Control-FREEC software was used to compare read numbers between tumors and germline control in order to estimate copy-number alterations in tumors.
(A) Genome-wide copy-number alterations in all malignancies (top row),Nf1 tumors alone (middle row), andwild-type (WT) tumors alone (bottom row). Alternating
stripes indicate consecutive chromosomes, beginning with chromosome 1 at the far left. The proportion of samples showing gain is displayed in red, and loss in
blue. Significantly altered areas, as calculated using STAC (Diskin et al., 2006), are indicated by heatmap bars directly above the chromosomal area for gain, and
below for loss (p < 0.05 shown). Overall,Nf1mutant-derived samples showed far more copy-number losses than gains (23% versus 8%), while wild-type-derived
tumors showed the opposite pattern, demonstrating fewer losses than gains (9% versus 29%).
(legend continued on next page)
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Table 2. Pathway Analysis
Molecular and
Cellular Functions
No. of
Molecules p Value
WT Sarcomas
Cellular assembly
and organization
155 7.07 3 1007  6.33 3 1003
Cellular function
and maintenance
163 7.07 3 1007  5.52 3 1003
Cell morphology 198 8.97 3 1007  5.88 3 1003
Cell cycle 28 2.32 3 1006  5.50 3 1003
Cell death
and survival
269 2.66 3 1006  5.50 3 1003
Nf1+/ Sarcomas
Cellular assembly
and organization
139 7.02 3 1005  2.04 3 1002
Cellular function
and maintenance
166 7.02 3 1005  2.18 3 1002
Cellular compromise 24 1.17 3 1004  2.18 3 1002
DNA replication,
recombination,
and repair
25 1.17 3 1004  1.99 3 1002
Cell death and survival 68 1.53 3 1004  2.09 3 1002
Ingenuity Variant Analysis software (http://www.ingenuity.com/products/
variant-analysis) was used to identify recurrently mutated pathways for
wild-type and Nf1 sarcomas. Shown is the number of molecules from
each pathway where there is a non-synonymous SNV in the gene in
one or more of our sarcomas. A right-tailed Fisher’s exact test was
used to calculate p values by considering (1) the number of focus genes
that participate in that process and (2) the total number of genes that are
known to be associated with that process in the selected reference set.Sjo¨blom et al. (2006) showed that C to T transitions were the
dominant substitution in colorectal cancers, while these sub-
stitutions were significantly less prevalent in breast cancers.
Discrete mutagens can also produce distinct signatures that
reflect the molecular lesions produced by the chemical
mechanism of action, as is the case of N-methyl-N-nitrosourea
(MNU)-induced GG(T/A) transitions (Westcott et al., 2015).
The underlying mechanisms for these differences are not well-
defined, although the nature of these differences may implicate
specific processes. Mutational signatures found in tumors
arising after exposure to IR or other known mutagens are likely
to reflect not only the DNA damage specific to the mutagen
but also the influence of repair mechanisms and selection pres-
sures inherent in tumorigenesis. The best understoodmutational
signature is associated with UV-induced mutagenesis, which is
associated with the production of dipyrimidine dimers that are(B) Unsupervised hierarchical clustering analysis was performed on copy-number
into groups sharing similar patterns of copy-number alterations. The heatmap s
number, blue indicating loss, and red indicating gain. See also Tables S8 and S9
(C) Venn diagrams depicting (left) the number of genes affected by significant co
(blue), or both (intersection) and (right) the number of genes affected by signifi
sarcomas (green), or altered in both (intersection).
(D) Bar graph displays the percentage of genes in the COSMIC database that inv
sarcomas, or (right) wild-type sarcomas. Student’s t test, *p < 0.05.
Cell Repclearly apparent in UV-associated tumors (Alexandrov et al.,
2013a; Bykov et al., 1998). Although IR is utilized in modern
medicine, in contrast to the aforementioned mutagens its ef-
fects are poorly characterized from a genome- or exome-wide
perspective.
Analyzing non-synonymous variants, we identified three sta-
ble mutational signatures suggestive of operative mutational
processes in IR-induced tumorigenesis. Mutational analysis
detected biases in the frequencies of particular base substitu-
tions within discrete sequence contexts. Our data indicate that
flanking bases can influence the rate of C/G and T/G substi-
tutions, as evidenced by the prominence of these substitutions
patterns in signature 3. These data suggest the importance of
the local sequence conformation influencing stability and enzy-
matic repair. Signature analysis also identified a transcriptional
strand bias for specific substitution types and contexts, which
may implicate processes such as transcription-coupled repair
that operate in a strand-specific fashion.
Synonymous variants are commonly viewed as passenger
mutations, but recent literature suggests that some synonymous
mutations may function as drivers of cancer development
(Supek et al., 2014). To determine whether synonymous variants
might harbor unique mutational signatures, we performed NMF
analysis on the synonymous variants alone (1,990 SNVs). In
this analysis, the original first two signatures were reproducibly
extracted from the synonymous variants, but the third signature
was unstable and was not reproduced. This signature instability
might reflect an underlying difference between synonymous
and non-synonymous mutations, a possibility we are unable to
confirm or reject given the small number of variants. Overall,
these findings indicate significant similarities with regard to
trinucleotide signature between synonymous and non-synony-
mous. However, further study is clearly needed to better define
possible differences between synonymous and non-synony-
mous variants and their biologic impact.
The three mutational signatures identified were present in
malignancies from both wild-type and Nf1 mutant mice, and
our analysis failed to identify an Nf1-specific trinucleotide signa-
ture. This suggests that the mutagenic IR exposure, rather than
the tested genetic backgrounds, primarily influenced the devel-
opment of these signatures. Our signatures are also distinct
from those seen in previous analyses of mutagen-induced tu-
mors (Alexandrov et al., 2013a).
These data contrast with other studies comparing mutational
landscapes of carcinogen-based models of cancer. Westcott
et al. (2015) compared mutation burden between mutant Kras,
methyl-nitrosurea, and urethane-induced lung cancer models
and found that Kras mutant lung cancers harbored signifi-
cantly fewer SNVs compared to carcinogen-associated tumorsvariation (CNV) data to organize sarcomas fromwild-type andNf1mutant mice
hows CNVs smoothed into 15-kb windows with white indicating normal copy
.
py-number changes that are gained in all sarcomas (red), lost in all sarcomas
cant copy-number changes that are altered in Nf1 sarcomas (tan), wild-type
olve either (left) copy-number gain or loss in all sarcomas, (middle) Nf1 mutant
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Table 3. Recurrently Mutated Genes
Chromosome Gene Name
Variant
Count, All
Variant Count,
Non-Synonymous Protein Name
1 Mroh2a 38 27 Maestro heat-like repeat family member 2A
1 Hjurp 35 29 Holliday junction recognition protein
1 Ugt1a1 30 22 UDP glucuronosyltransferase 1 family, polypeptide A1
9 Mtmr2 25 21 Myotubularin related protein 2
6 Tmcc1 24 16 Transmembrane and coiled coil domains 1
1 Itln1 22 8 Intelectin 1
16 Muc4 21 17 Mucin 4
11 Obscn 20 10 Obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF
1 Cd244 16 13 CD244 natural killer cell receptor 2B4
8 Kars 16 10 Lysyl-tRNA synthetase
5 Nxpe5 14 4 Neurexophilin and PC-esterase domain family, member 5
17 Foxn2 14 12 Forkhead box N2
4 Skint6 13 12 Selection and upkeep of intraepithelial T cells 6
6 Klra1 13 11 Killer cell lectin-like receptor, subfamily A, member 1
7 Psg18 12 7 Pregnancy specific glycoprotein 18
9 Cbl 12 12 Casitas B-lineage lymphoma
6 Klra10 11 10 Killer cell lectin-like receptor subfamily A, member 10
6 Klra4 11 11 Killer cell lectin-like receptor, subfamily A, member 4
7 Mrgpra9 11 8 MAS-related GPR, member A9
17 Plin4 11 2 Perilipin 4
X Tro 11 11 Trophinin
4 Thrap3 10 6 Thyroid hormone receptor associated protein 3
13 Mplkip 10 9 M-phase-specific PLK1-interacting protein
13 Taf9 10 5 TAF9 RNA polymerase II, TATA box binding protein
(TBP)-associated factor
The most frequently mutated genes are listed in the table, with the total number of variants identified across all 25 samples and number of non-
synonymous only. Variants in genes known to be pseudo-genes, in repetitive regions, or seen at high frequency across all samples, and thus likely
to be errors, were removed.(Westcott et al., 2015). Our analysis of IR-induced tumors
demonstrated variable numbers of SNVs and comparatively
fewer SNVs than identified in MNU-induced malignancies. The
relatively low rate of somatic SNVs in IR-induced malignancies
was unexpected, given that mutagen-associated malignancies
in mice and humans often have relatively high mutation rates
(Alexandrov et al., 2013a; Westcott et al., 2015). Our data indi-
cate that IR-associated malignancies do not necessarily harbor
high numbers of somatic SNVs and that diverse organs muta-
genized by IR share similar numbers of mutations.
The SNV rate in different genetically mutant mouse back-
grounds may reflect underlying fundamental differences be-
tween tumorigenesis driven by loss of a tumor suppressor
gene as compared to activation of an oncogene. Nf1 loss and
Kras activation both promote ras signaling; however, Nf1 loss
does not phenocopy oncogenic Kras expression and is clearly
a weaker driver of tumor formation (Cichowski and Jacks,
2001; Morcos et al., 1996). A potential consequence of this
inherent difference in molecular function is that tumorigenesis
driven by Nf1 loss, as occurs in our mouse models, may require
a greater number of cooperating mutations as compared to
Kras-driven tumors. The requirement for accumulation of coop-1922 Cell Reports 12, 1915–1926, September 22, 2015 ª2015 The Aerating mutational events could certainly influence tumor
development and behavior by limiting the growth potential of
developing tumors. The clinical course of the NF1 syndrome
may reflect this possibility, as many tumors in NF1 patients are
slowly progressive (Friedman, 2002). In order to understand
disease and specifically cancer progression in the context of
inherited tumor predisposition syndromes, additional studies
are needed to characterize and explain the mutational conse-
quences of germline mutations in NF1 and other germline muta-
tions known to affect tumor susceptibility in humans.
The effects of genotoxin exposure also extend to cancer
therapy, because IR and genotoxic chemotherapy are standard
treatments in the management of many malignancies. Indeed,
the mutational signatures associated with genotoxin therapy
can be found in treated cancers. Johnson et al. (2014) examined
how glioma therapies, particularly treatment with the alkylator
temozolomide, influence the genomes of human gliomas. This
work revealed that temozolomide treatment is associated with
the development of a hypermutated genome, a finding that rai-
ses concern about how alkylator therapy itself promotes the
evolution of a low grade glioma into a more aggressive and
histologically high grade malignancy. Our results suggest thatuthors
Figure 4. Ras Pathway Genes Mutated in
IR-Induced Malignancies
The table displays Ras pathway genes that
demonstrate significant copy-number changes
(either loss or gain), missense mutations, and/or
stop-gain mutations in IR-induced neoplasms.IR-treated cancers may similarly harbor mutational signatures
distinguishable from other genotoxic cancer therapies such as
alkylating chemotherapy, and further work in this area may
yield important insights into tumor evolution. These issues areCell Reports 12, 1915–1926, Sepimportant considerations as cancer ther-
apy increasingly must consider potential
mechanisms of resistance to therapy. If
genomic injury resulting from initial can-
cer therapy shapes cancer evolution and
subsequent resistance, understanding
this process may inform attempts to miti-
gate this process and improve treatment
efficacy.
Previous studies have characterized
the somatic copy-number profiles of
tumors from different histologies (Zack
et al., 2013). We saw comparable levels
of genomic disruption in our IR-induced
tumors and similarly observed no recur-
rent changes that segregate with histol-
ogy. However, we did observe signifi-
cantly more copy-number gain than loss
in our wild-type tumors, and the converse
in tumors from Nf1 heterozygous mice.
This was particularly pronounced on
chromosome 11, which shows loss in
close to 50% of Nf1 tumors sequenced.
We have shown in a previous LOH study
(Choi et al., 2012) using our mouse model
that tumors were rendered effectively Nf1
null due to preferential loss of the wild-
type Nf1 allele on chromosome 11. Inter-
estingly, this finding is consistent with
the observation made in earlier work that
lung tumors arising from Kras mutant
mice harbor copy-number alterations dis-
tinguishing them from mutagen-induced
tumors (Westcott et al., 2015). Taken
together, these findings suggest that
copy-number alterations represent an
efficient route to tumorigenesis and may
be selected for in tumors with discrete
driver mutations.
We speculate that the bias of Nf1-
derived tumors from our mouse model
to harbor copy-number loss and wild-
type-derived tumors to favor copy-num-
ber gain may reflect multiple possible
mechanisms. Given that neurofibromin is
not known to have a role in DNA repair,and earlier experiments we performed failed to detect a differ-
ence in dsDNAbreak formation or repair withNf1 loss (Nakamura
et al., 2011), it appears unlikely that the difference in copy-num-
ber alteration reflects an intrinsic difference in the basal genomictember 22, 2015 ª2015 The Authors 1923
stability of Nf1+/ cells. It is possible that in neoplasms arising
from Nf1 mutant backgrounds, alterations in pathways respon-
sible for genomic stability are preferentially altered and could
lead, over successive divisions, to cumulative chromosomal
losses. It is also possible that ionizing radiation induces different
patterns of genomic injury in wild-type and Nf1 mutant cells on
the basis of chromatin architecture and environments. These
ideas remain speculative, as the influence of germline Nf1muta-
tions on genome stability and structural variation is not well-
defined. Malignant peripheral nerve sheath tumors (MPNSTs),
which are malignancies characteristic of the NF1 syndrome
(Kresse et al., 2008; Mantripragada et al., 2008, 2009; Thomas
et al., 2015), have been described to harbor both copy-number
gains and losses, with gains outnumbering losses (Kresse
et al., 2008; Mantripragada et al., 2009). The underlying basis
for this is also not understood, and whether this pattern of
copy-number alterations is generalizable to all NF1 mutant
tumors remains unclear. These questions highlight the need for
further analyses of NF1-driven tumorigenesis and the impact of
germline tumor suppressor mutations in general.
In summary, this work characterizes the mutational processes
in IR-induced malignancies and yields important information
concerning both mutagenic exposure and the influence of a
germline mutation in the Nf1 tumor suppressor gene. We iden-
tify stable mutational signatures that can serve as a basis for
understanding how IR exposure and Nf1 heterozygosity can
each promote the development of malignancies. This work
also highlights the utility of genetically engineeredmousemodels
of cancer to study the mutational consequences of germline het-
erozygosity for tumor suppressor genes.
EXPERIMENTAL PROCEDURES
Mouse Model
Nf1+/ mice were generated as previously described. In brief, Nf1+/ mice
maintained in the 129/Sv background (Jacks et al., 1994) were crossed with
wild-type C57Bl/6 mice. Six- to eight-week-old mice were given focal, frac-
tionated irradiation delivered at a rate of five fractions per week, with one frac-
tion per day as previously described (Choi et al., 2012; Nakamura et al., 2011).
Tumor samples used in this analysis were obtained after animals were eutha-
nized, and all animal procedures were approved by the University of California,
San Francisco Institutional Animal Care and Use Committee (approved proto-
col numbers: AN078941 and AN080665). These practices conform to regula-
tions defined by the Animal Welfare Act and the US Department of Agriculture.
Cell Lines and Cell Culture Conditions
All tumor cell lines were grown in DMEM (4,500 mg/L glucose, Life Technolo-
gies) supplemented with 10% fetal bovine serum (GIBCO-BRL, Invitrogen),
penicillin, and streptomycin. Cells were grown in a humidified incubator con-
taining 8% carbon dioxide at 37C.
Whole Exome Sequencing
Whole exome sequencing was performed using the Agilent SureSelect mouse
all exon kit. Captured material was indexed and sequenced on the Illumina
GAII and HiSeq2000 platform at the Wellcome Trust Sanger Institute. Suc-
cessfully sequenced reads were then aligned to mouse reference genome
(GRCm38) followed by the number of quality control routines (e.g., base quality
score recalibration, realignment around InDels). We used the Cake variants
detection pipeline (Perna et al., 2015; Rashid et al., 2013) to identify somatic
as well as germline variants. A stringent variant caller overlapping strategy
has been adapted to minimize false positive rates. Those detected by at least
four of the five algorithms (embedded within Cake: Bambino; Varscan 2; Mpi-1924 Cell Reports 12, 1915–1926, September 22, 2015 ª2015 The Aleup; SomaticSniper; and Mutect) were subsequently filtered for depth, known
mouse variations (Keane et al., 2011), strong germline activity, and functional
impact to produce a cleaner list of mutations (Table S1).
Copy-Number Analysis
Using the exome sequencing data, we identified regions of CNV in tumor DNAs
relative to the matched normal (129/Sv-C576BL/6 heterozygote) using Con-
trol-FREEC with default parameters (Boeva et al., 2012). Analysis was
restricted to the region selected by the SureSelectXT mouse exome capture
kit (Agilent). CNVs were smoothed into 15-kb segments. Regions with a low
call rate (called in less than one-third of samples) and invariant regions were
removed. The Euclidian distances between samples were calculated using
theWGCNAR software package (Langfelder and Horvath, 2008), and samples
were clustered using Ward’s method. The resulting dendogram demonstrates
the relatedness between samples based on genome-wide CNV patterns.
Pathway Analysis
A list of Ras signaling pathway genes was obtained from KEGG pathway
hsa04014 (http://www.genome.jp/dbget-bin/www_bget?pathway+hsa04014).
Statistical Analysis
We performed NMF following protocols developed by WTSI (Alexandrov et al.,
2013b), starting with their MATLAB scripts downloaded from http://www.
mathworks.com/matlabcentral/fileexchange/38724-wtsi-mutational-signature-
framework. Their scripts were modified only as necessary to accommodate our
data and computer.We first replicated the signatures reported byWTSI (Alexan-
drovet al., 2013b;Nik-Zainal et al., 2012) to validate our procedures.We then fol-
lowed theseprocedureson the followingdatasets: (1)25samples (22 tumorsand
3 cell lines derived from 3 of the tumors) with 192 substitution types (6 substitu-
tions using the pyrimidine as reference3 2 strands3 four 50 neighbors3 four 30
neighbors) for both synonymous and non-synonymous mutations; (2) the same
analysis except excluding synonymous mutations; (3) 22 tissue samples,
excluding3cell lines, using the sameparametersas (1); and (4) the sameanalysis
as (1) except collapsing strands for 96 substitution types.
For comparison withWTSI human coefficients (Alexandrov et al., 2013a), our
coefficients were normalized to the mouse trinucleotide frequencies (Frenkel
et al., 2011) as NrmSx in Table S5 and as IrrMsex in Table S6.
All but two of the frequency, contingency table, and correlation analyses
were performed with standard Microsoft Excel formulae and functions. One
exception is Fisher’s exact test (or Fisher-Freeman-Halton test) used to
compare substitution frequencies by strand (Table S7), where expected
frequencies were too small for a chi-square statistic. The SPSS Exact Tests
module completed a Monte Carlo estimation based on a random sample of
100,000 tables, providing a two-sided p value of 0.000. The other is Fisher’s
exact test used in Table 2 for separate 23 2 tables done as part of the pathway
analysis by IPA, the Ingenuity software.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and nine tables and can be
foundwith this article online at http://dx.doi.org/10.1016/j.celrep.2015.08.015.
AUTHOR CONTRIBUTIONS
J.L.N. conceived the project, obtained resources and funding, and adminis-
tered and supervised the work. A.L.S. performed the formal analysis. P.R.D.
and A.O.N. performed the statistical analysis. K.Y. performed the laboratory
analysis. M.R. performed exome sequencing, alignment, and variant calling.
J.L.N. and A.L.S. wrote the original draft, and all authors reviewed and edited
the final manuscript.
ACKNOWLEDGMENTS
We thank Allan Balmain, Benjamin Braun, Kevin Shannon, and their labs for
helpful discussions. Kyle Halliwell provided help with bioinformatics analysis.
We thank David Adams for helpful discussions and reading the manuscript.uthors
J.L.N. was supported by grants from the NIH, National Cancer Institute
(1K08CA115476), UCSF Breast SPORE Program, Alex’s Lemonade Stand
Foundation, St. Baldrick’s Foundation Scholar Award, and Sammy and Kari
Hagar and the Hagar Family Foundation.
Received: May 2, 2015
Revised: July 8, 2015
Accepted: August 5, 2015
Published: September 3, 2015
REFERENCES
Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Bian-
kin, A.V., Bignell, G.R., Bolli, N., Borg, A., Børresen-Dale, A.L., et al.; Australian
Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC
MMML-Seq Consortium; ICGC PedBrain (2013a). Signatures of mutational
processes in human cancer. Nature 500, 415–421.
Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Campbell, P.J., and Stratton,
M.R. (2013b). Deciphering signatures of mutational processes operative in
human cancer. Cell Rep. 3, 246–259.
Armstrong, G.T., Liu, Q., Yasui, Y., Huang, S., Ness, K.K., Leisenring, W., Hud-
son, M.M., Donaldson, S.S., King, A.A., Stovall, M., et al. (2009a). Long-term
outcomes among adult survivors of childhood central nervous system malig-
nancies in the Childhood Cancer Survivor Study. J. Natl. Cancer Inst. 101,
946–958.
Armstrong, G.T., Liu, Q., Yasui, Y., Neglia, J.P., Leisenring, W., Robison, L.L.,
andMertens, A.C. (2009b). Late mortality among 5-year survivors of childhood
cancer: a summary from the Childhood Cancer Survivor Study. J. Clin. Oncol.
27, 2328–2338.
Bhatia, S., and Sklar, C. (2002). Second cancers in survivors of childhood
cancer. Nat. Rev. Cancer 2, 124–132.
Boeva, V., Popova, T., Bleakley, K., Chiche, P., Cappo, J., Schleiermacher, G.,
Janoueix-Lerosey, I., Delattre, O., and Barillot, E. (2012). Control-FREEC: a
tool for assessing copy number and allelic content using next-generation
sequencing data. Bioinformatics 28, 423–425.
Bykov, V.J., Jansen, C.T., and Hemminki, K. (1998). High levels of dipyrimidine
dimers are induced in human skin by solar-simulating UV radiation. Cancer Ep-
idemiol. Biomarkers Prev. 7, 199–202.
Choi, G., Huang, B., Pinarbasi, E., Braunstein, S.E., Horvai, A.E., Kogan, S.,
Bhatia, S., Faddegon, B., and Nakamura, J.L. (2012). Genetically mediated
Nf1 loss in mice promotes diverse radiation-induced tumors modeling second
malignant neoplasms. Cancer Res. 72, 6425–6434.
Cichowski, K., and Jacks, T. (2001). NF1 tumor suppressor gene function:
narrowing the GAP. Cell 104, 593–604.
Cingolani, P., Platts, A., Wang, L., Coon, M., Nguyen, T., Wang, L., Land, S.J.,
Lu, X., and Ruden, D.M. (2012). A program for annotating and predicting the
effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of
Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6, 80–92.
Crump, M., and Hodgson, D. (2009). Secondary breast cancer in Hodgkin’s
lymphoma survivors. J. Clin. Oncol. 27, 4229–4231.
Diskin, S.J., Eck, T., Greshock, J., Mosse, Y.P., Naylor, T., Stoeckert, C.J., Jr.,
Weber, B.L., Maris, J.M., and Grant, G.R. (2006). STAC: A method for testing
the significance of DNA copy number aberrations across multiple array-CGH
experiments. Genome Res. 16, 1149–1158.
Frenkel, Z.M., Bettecken, T., and Trifonov, E.N. (2011). Nucleosome DNA
sequence structure of isochores. BMC Genomics 12, 203.
Friedman, J.M. (2002). Neurofibromatosis 1: clinical manifestations and diag-
nostic criteria. J. Child. Neurol. 17, 548–554, discussion 571–542, 646–551.
Green, P., Ewing, B., Miller, W., Thomas, P.J., and NISC Comparative
Sequencing Program, and Green, E.D. (2003). Transcription-associated muta-
tional asymmetry in mammalian evolution. Nat. Genet. 33, 514–517.
Henderson, T.O., Whitton, J., Stovall, M., Mertens, A.C., Mitby, P., Friedman,
D., Strong, L.C., Hammond, S., Neglia, J.P., Meadows, A.T., et al. (2007). Sec-Cell Repondary sarcomas in childhood cancer survivors: a report from the Childhood
Cancer Survivor Study. J. Natl. Cancer Inst. 99, 300–308.
Jacks, T., Shih, T.S., Schmitt, E.M., Bronson, R.T., Bernards, A., and Wein-
berg, R.A. (1994). Tumour predisposition in mice heterozygous for a targeted
mutation in Nf1. Nat. Genet. 7, 353–361.
Johnson, B.E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C.Y.,
Fouse, S.D., Yamamoto, S., Ueda, H., Tatsuno, K., et al. (2014). Mutational
analysis reveals the origin and therapy-driven evolution of recurrent glioma.
Science 343, 189–193.
Keane, T.M., Goodstadt, L., Danecek, P., White, M.A., Wong, K., Yalcin, B.,
Heger, A., Agam, A., Slater, G., Goodson, M., et al. (2011). Mouse genomic
variation and its effect on phenotypes and gene regulation. Nature 477,
289–294.
Kresse, S.H., Ska˚rn, M., Ohnstad, H.O., Namløs, H.M., Bjerkehagen, B.,
Myklebost, O., and Meza-Zepeda, L.A. (2008). DNA copy number changes
in high-grade malignant peripheral nerve sheath tumors by array CGH. Mol.
Cancer 7, 48.
Langfelder, P., and Horvath, S. (2008). WGCNA: an R package for weighted
correlation network analysis. BMC Bioinformatics 9, 559.
Mantripragada, K.K., Spurlock, G., Kluwe, L., Chuzhanova, N., Ferner, R.E.,
Frayling, I.M., Dumanski, J.P., Guha, A., Mautner, V., and Upadhyaya, M.
(2008). High-resolution DNA copy number profiling of malignant peripheral
nerve sheath tumors using targeted microarray-based comparative genomic
hybridization. Clin. Cancer Res. 14, 1015–1024.
Mantripragada, K.K., Dı´az de Sta˚hl, T., Patridge, C.,Menzel, U., Andersson, R.,
Chuzhanova, N., Kluwe, L., Guha, A., Mautner, V., Dumanski, J.P., and Upad-
hyaya, M. (2009). Genome-wide high-resolution analysis of DNA copy number
alterations in NF1-associated malignant peripheral nerve sheath tumors using
32K BAC array. Genes Chromosomes Cancer 48, 897–907.
Mao, J.H., Li, J., Jiang, T., Li, Q., Wu, D., Perez-Losada, J., DelRosario, R.,
Peterson, L., Balmain, A., and Cai, W.W. (2005). Genomic instability in radia-
tion-induced mouse lymphoma from p53 heterozygous mice. Oncogene 24,
7924–7934.
Mao, J.H.,Wu, D., DelRosario, R., Castellanos, A., Balmain, A., and Perez-Los-
ada, J. (2008). Atm heterozygosity does not increase tumor susceptibility to
ionizing radiation alone or in a p53 heterozygous background. Oncogene 27,
6596–6600.
Meadows, A.T., Friedman, D.L., Neglia, J.P., Mertens, A.C., Donaldson, S.S.,
Stovall, M., Hammond, S., Yasui, Y., and Inskip, P.D. (2009). Second neo-
plasms in survivors of childhood cancer: findings from the Childhood Cancer
Survivor Study cohort. J. Clin. Oncol. 27, 2356–2362.
Morcos, P., Thapar, N., Tusneem, N., Stacey, D., and Tamanoi, F. (1996). Iden-
tification of neurofibromin mutants that exhibit allele specificity or increased
Ras affinity resulting in suppression of activated ras alleles. Mol. Cell. Biol.
16, 2496–2503.
Nakamura, J.L., Phong, C., Pinarbasi, E., Kogan, S.C., Vandenberg, S., Horvai,
A.E., Faddegon, B.A., Fiedler, D., Shokat, K., Houseman, B.T., et al. (2011).
Dose-dependent effects of focal fractionated irradiation on secondary malig-
nant neoplasms in Nf1 mutant mice. Cancer Res. 71, 106–115.
Nik-Zainal, S., Alexandrov, L.B., Wedge, D.C., Van Loo, P., Greenman, C.D.,
Raine, K., Jones, D., Hinton, J., Marshall, J., Stebbings, L.A., et al.; Breast
Cancer Working Group of the International Cancer Genome Consortium
(2012). Mutational processes molding the genomes of 21 breast cancers.
Cell 149, 979–993.
Perna, D., Karreth, F.A., Rust, A.G., Perez-Mancera, P.A., Rashid, M., Iorio, F.,
Alifrangis, C., Arends, M.J., Bosenberg, M.W., Bollag, G., et al. (2015). BRAF
inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF
mouse melanoma model. Proc. Natl. Acad. Sci. USA 112, E536–E545.
Rashid, M., Robles-Espinoza, C.D., Rust, A.G., and Adams, D.J. (2013). Cake:
a bioinformatics pipeline for the integrated analysis of somatic variants in can-
cer genomes. Bioinformatics 29, 2208–2210.
Rubin, A.F., and Green, P. (2009). Mutation patterns in cancer genomes. Proc.
Natl. Acad. Sci. USA 106, 21766–21770.orts 12, 1915–1926, September 22, 2015 ª2015 The Authors 1925
Sjo¨blom, T., Jones, S., Wood, L.D., Parsons, D.W., Lin, J., Barber, T.D.,
Mandelker, D., Leary, R.J., Ptak, J., Silliman, N., et al. (2006). The consensus
coding sequences of human breast and colorectal cancers. Science 314,
268–274.
Stephen, A.G., Esposito, D., Bagni, R.K., and McCormick, F. (2014). Dragging
ras back in the ring. Cancer Cell 25, 272–281.
Stephens, P., Edkins, S., Davies, H., Greenman, C., Cox, C., Hunter, C.,
Bignell, G., Teague, J., Smith, R., Stevens, C., et al. (2005). A screen of the
complete protein kinase gene family identifies diverse patterns of somatic
mutations in human breast cancer. Nat. Genet. 37, 590–592.
Supek, F., Min˜ana, B., Valca´rcel, J., Gabaldo´n, T., and Lehner, B. (2014).
Synonymous mutations frequently act as driver mutations in human cancers.
Cell 156, 1324–1335.
Thomas, L.E., Winston, J., Rad, E., Mort, M., Dodd, K.M., Tee, A.R., McDyer,
F., Moore, S., Cooper, D.N., and Upadhyaya, M. (2015). Evaluation of copy
number variation and gene expression in neurofibromatosis type-1-associated
malignant peripheral nerve sheath tumours. Hum. Genomics 9, 3.
Tucker, M.A., D’Angio, G.J., Boice, J.D., Jr., Strong, L.C., Li, F.P., Stovall, M.,
Stone, B.J., Green, D.M., Lombardi, F., Newton, W., et al. (1987). Bone
sarcomas linked to radiotherapy and chemotherapy in children. N. Engl. J.
Med. 317, 588–593.
Tukenova, M., Guibout, C., Hawkins, M., Quiniou, E., Mousannif, A., Pacque-
ment, H., Winter, D., Bridier, A., Lefkopoulos, D., Oberlin, O., et al. (2011).
Radiation therapy and late mortality from second sarcoma, carcinoma, and1926 Cell Reports 12, 1915–1926, September 22, 2015 ª2015 The Ahematological malignancies after a solid cancer in childhood. Int. J. Radiat.
Oncol. Biol. Phys. 80, 339–346.
Ullrich, R.L., Jernigan, M.C., Satterfield, L.C., and Bowles, N.D. (1987). Radia-
tion carcinogenesis: time-dose relationships. Radiat. Res. 111, 179–184.
Ullrich, R.L., Bowles, N.D., Satterfield, L.C., and Davis, C.M. (1996). Strain-
dependent susceptibility to radiation-induced mammary cancer is a result of
differences in epithelial cell sensitivity to transformation. Radiat. Res. 146,
353–355.
Wei, X., Walia, V., Lin, J.C., Teer, J.K., Prickett, T.D., Gartner, J., Davis, S.,
Stemke-Hale, K., Davies, M.A., Gershenwald, J.E., et al.; NISC Comparative
Sequencing Program (2011). Exome sequencing identifies GRIN2A as
frequently mutated in melanoma. Nat. Genet. 43, 442–446.
Westcott, P.M., Halliwill, K.D., To, M.D., Rashid, M., Rust, A.G., Keane, T.M.,
Delrosario, R., Jen, K.Y., Gurley, K.E., Kemp, C.J., et al. (2015). The mutational
landscapes of genetic and chemical models of Kras-driven lung cancer.
Nature 517, 489–492.
Yong, R.L., Yang, C., Lu, J., Wang, H., Schlaff, C.D., Tandle, A., Graves, C.A.,
Elkahloun, A.G., Chen, X., Zhuang, Z., and Lonser, R.R. (2014). Cell transcrip-
tional state alters genomic patterns of DNA double-strand break repair in
human astrocytes. Nat. Commun. 5, 5799.
Zack, T.I., Schumacher, S.E., Carter, S.L., Cherniack, A.D., Saksena, G.,
Tabak, B., Lawrence, M.S., Zhsng, C.Z., Wala, J., Mermel, C.H., et al.
(2013). Pan-cancer patterns of somatic copy number alteration. Nat. Genet.
45, 1134–1140.uthors
